Knowledge Hub

Respiratory Pathogen Statistics April 2026

This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during April 2026

Western Cape Province Antimicrobial Surveillance Data 2025

PathCare antimicrobial susceptibility data for common community-acquired organisms isolated from patients in the Western Cape province during 2025 have been updated.

Update on laboratory testing of ophthalmology samples

Ophthalmology specimens pose unique challenges for diagnostic microbiology. Samples should be optimally collected and transported to the laboratory. A special ophthalmology specimen collection pack and request form is available to facilitate optimal testing.

The use of the sFlt-1/PLGF ratio tailored specifically for the South African Population

Hypertensive disorders of pregnancy, particularly pre-eclampsia (PE), complicate around 8% of pregnancies worldwide, and account for about 500 000 perinatal deaths annually.

Anticonvulsant Therapeutic Drug Monitoring

We are proud to announce the expansion of our anticonvulsant therapeutic drug monitoring (TDM) offering to enhance personalised pharmacotherapy.

Respiratory Pathogen Statistics March 2026

This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during March 2026

Respiratory Pathogen Statistics February 2026

This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during February 2026 (epidemiological weeks 6-9).

Approach to investigating Blood Culture-Negative Endocarditis (BCNE)

PathCare introduces a new multiplex PCR panel to detect Tick-Borne pathogens

Optimising Clostridioides difficile Diagnosis

Stool samples sent for C. difficile testing at the reference laboratory in Cape Town, Pathcare will perform routine two-step testing following a positive C. difficile detection on stool PCR testing.

With regard to Designated Service Provider (DSP) Contracts the following law is pertinent for service providers who are not a DSP:

  1. In terms of Section 59 (2) of the Medical Schemes Act 131 of 1998 the medical scheme must pay valid invoices within 30 days of receipt thereof or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct the invoice.
  2. Where services are in respect of medical emergencies or involuntarily obtained services for PMB conditions, the scheme has to pay for the full cost of the services provided without deduction or co-payment or limiting the tariff amount. (Regulation 8 (1) of the Medical Schemes Act no. 131 of 1998.)
  3. DOH notice 214 of 2021 requires that a scheme pays for services provided at the same rate and in terms of the same rules as they pay their DSPs in respect of services voluntarily obtained, whether they are PMBs or not.
  4. The process followed in respect of appointing a DSP is required to be fair, equitable, transparent, competitive or cost effective as required in terms of Notice 214 of the DOH.

In summary:

  1. The law protects the patient’s choice to use their laboratory of choice, even if it is not a DSP, and the scheme is still obliged to reimburse us at the scheme rate for valid claims.
  2. This is true for PMB conditions as well as non-PMB conditions.
  3. The medical scheme must pay valid invoices within 30 days or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct invoice.
  4. A scheme must pay for the services provided at a tariff not less than what they would pay a DSP.
  5. Should any patient have a valid claim rejected because we are not a DSP, we can assist.